MedTrace Logo

Effects of Autogenic Inhibition Versus Reciprocal Inhibition in Individuals With Lower Cross Syndrome

NCT07526051 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-05-20

No results posted yet for this study

Summary

This study examines the effects of autogenic inhibition (PFS) versus reciprocal inhibition in individuals with lower cross syndrome

Conditions

  • Lower Cross Syndrome

Interventions

PROCEDURE

Autogenic Inhibition (PFS) Group A

Patient will receive a four-week physiotherapy program with 3 sessions per week. Each session with heat application followed by supervised stretching and strengthening exercises. Participants in group A will receive Autogenic Inhibition (PFS) 10 minutes TENS \& Heating Pad Autogenic Inhibition for 5 sec 5 reps, 5 sec hold,1 set Frequency: 12 sessions for 4 weeks (3 sessions per week and day of rest between sessions) Total Treatment Time 30 minutes each session Strengthening Exercises for Hip and Core Muscles

PROCEDURE

Reciprocal Inhibition Group B

Patient will receive a four-week physiotherapy program with 3 sessions per week. Each session with heat application followed by supervised stretching and strengthening exercises. Participants in group B will receive Reciprocal Inhibition 10 minutes TENS \& Heating Pad Inhibition for 5 sec 5 reps,5 sec hold,1 set Frequency: 12 sessions for 4 weeks (3 sessions per week and day of rest between sessions) Total Treatment Time 30 minutes each session Strengthening Exercises for Hip and Core Muscles

Sponsors & Collaborators

  • Foundation University Islamabad

    lead OTHER

Principal Investigators

  • Zobia Noor, DPT · Foundation University Islamabad

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-20
Primary Completion
2026-07-01
Completion
2026-07-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07526051 on ClinicalTrials.gov